Jane J. Zara

Array ( [id] => 10202560 [patent_doc_number] => 20150087549 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-26 [patent_title] => 'METHODS OF USING TISSUE BIOMARKERS FOR INDICATION OF PROGRESSION FROM BARRETTS ESOPHAGUS TO ESOPHAGEAL ADENOCARCINOMA' [patent_app_type] => utility [patent_app_number] => 14/552132 [patent_app_country] => US [patent_app_date] => 2014-11-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 12367 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14552132 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11779314 [patent_doc_number] => 09388414 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-07-12 [patent_title] => 'Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases' [patent_app_type] => utility [patent_app_number] => 14/550025 [patent_app_country] => US [patent_app_date] => 2014-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 6 [patent_no_of_words] => 22899 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14550025 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11231236 [patent_doc_number] => 09458459 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-10-04 [patent_title] => 'Methods for enhancing utrophin production via inhibition of microRNA' [patent_app_type] => utility [patent_app_number] => 14/547795 [patent_app_country] => US [patent_app_date] => 2014-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 19 [patent_no_of_words] => 9162 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 118 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14547795 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11827636 [patent_doc_number] => 09724365 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-08-08 [patent_title] => 'Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies' [patent_app_type] => utility [patent_app_number] => 14/546755 [patent_app_country] => US [patent_app_date] => 2014-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 49 [patent_figures_cnt] => 64 [patent_no_of_words] => 34147 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14546755 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11344587 [patent_doc_number] => 09528991 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-12-27 [patent_title] => 'Individualized cancer therapy' [patent_app_type] => utility [patent_app_number] => 14/535789 [patent_app_country] => US [patent_app_date] => 2014-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 58 [patent_no_of_words] => 18854 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14535789 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15980581 [patent_doc_number] => 10670611 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-02 [patent_title] => Cardiovascular risk event prediction and uses thereof [patent_app_type] => utility [patent_app_number] => 15/509665 [patent_app_country] => US [patent_app_date] => 2014-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 23 [patent_no_of_words] => 35590 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15509665 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10362141 [patent_doc_number] => 20150247147 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-09-03 [patent_title] => 'MODULATORS OF COAGULATION FACTORS' [patent_app_type] => utility [patent_app_number] => 14/508609 [patent_app_country] => US [patent_app_date] => 2014-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 23663 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14508609 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11427995 [patent_doc_number] => 09566295 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-02-14 [patent_title] => 'GNAQ targeted dsRNA compositions and methods for inhibiting expression' [patent_app_type] => utility [patent_app_number] => 14/507086 [patent_app_country] => US [patent_app_date] => 2014-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 45126 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14507086 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13209563 [patent_doc_number] => 10119143 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-11-06 [patent_title] => Compositions and methods for inhibiting expression of the ALAS1 gene [patent_app_type] => utility [patent_app_number] => 15/027176 [patent_app_country] => US [patent_app_date] => 2014-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 61 [patent_figures_cnt] => 61 [patent_no_of_words] => 87876 [patent_no_of_claims] => 78 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15027176 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9799800 [patent_doc_number] => 20150011744 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-01-08 [patent_title] => 'Modifications for Antisense Compounds' [patent_app_type] => utility [patent_app_number] => 14/281646 [patent_app_country] => US [patent_app_date] => 2014-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 16746 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14281646 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10220453 [patent_doc_number] => 20150105447 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-16 [patent_title] => 'FIDGETIN-LIKE 2 AS A TARGET TO ENHANCE WOUND HEALING' [patent_app_type] => utility [patent_app_number] => 14/487221 [patent_app_country] => US [patent_app_date] => 2014-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 7331 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14487221 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10522914 [patent_doc_number] => 09249414 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-02-02 [patent_title] => 'Oligonucleotide compounds comprising non-nucleotide overhangs' [patent_app_type] => utility [patent_app_number] => 14/485828 [patent_app_country] => US [patent_app_date] => 2014-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 25 [patent_no_of_words] => 42893 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14485828 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9909508 [patent_doc_number] => 20150064709 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-05 [patent_title] => 'MODULATING GENE EXPRESSION WITH agRNA AND GAPMERS TARGETING ANTISENSE TRANSCRIPTS' [patent_app_type] => utility [patent_app_number] => 14/482950 [patent_app_country] => US [patent_app_date] => 2014-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8273 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14482950 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15666917 [patent_doc_number] => 10597679 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-24 [patent_title] => Switchable Cas9 nucleases and uses thereof [patent_app_type] => utility [patent_app_number] => 14/916683 [patent_app_country] => US [patent_app_date] => 2014-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 15817 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14916683 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11888258 [patent_doc_number] => 09758811 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-09-12 [patent_title] => 'Use of aptamers in proteomics' [patent_app_type] => utility [patent_app_number] => 14/477907 [patent_app_country] => US [patent_app_date] => 2014-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 8806 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14477907 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10997423 [patent_doc_number] => 20160194368 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-07 [patent_title] => 'CIRCULAR POLYNUCLEOTIDES' [patent_app_type] => utility [patent_app_number] => 14/915945 [patent_app_country] => US [patent_app_date] => 2014-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 153387 [patent_no_of_claims] => 58 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14915945 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10331888 [patent_doc_number] => 20150216893 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-06 [patent_title] => 'METHODS AND COMPOSITIONS FOR INHIBITING A MULTI-CANCER MESENCHYMAL TRANSITION MECHANISM' [patent_app_type] => utility [patent_app_number] => 14/458714 [patent_app_country] => US [patent_app_date] => 2014-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 13990 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14458714 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11902894 [patent_doc_number] => 09772324 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-09-26 [patent_title] => 'Use of inhibitors of leukotriene B4 receptor BLT2 for treating asthma' [patent_app_type] => utility [patent_app_number] => 14/446298 [patent_app_country] => US [patent_app_date] => 2014-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 44 [patent_no_of_words] => 22722 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14446298 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10926869 [patent_doc_number] => 20140329887 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-11-06 [patent_title] => 'MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY' [patent_app_type] => utility [patent_app_number] => 14/444406 [patent_app_country] => US [patent_app_date] => 2014-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 41645 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14444406 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10613828 [patent_doc_number] => 09333254 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-10 [patent_title] => 'Long term disease modification using immunostimulatory oligonucleotides' [patent_app_type] => utility [patent_app_number] => 14/335790 [patent_app_country] => US [patent_app_date] => 2014-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 28957 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 186 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14335790 [rel_patent_id] =>[rel_patent_doc_number] =>)